{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T06:54:48Z","timestamp":1696834488618},"reference-count":26,"publisher":"Japanese Association of Rural Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rural Med"],"published-print":{"date-parts":[[2020]]},"DOI":"10.2185\/jrm.2020-018","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T22:17:49Z","timestamp":1601504269000},"page":"225-229","source":"Crossref","is-referenced-by-count":0,"title":["Mizoribine treatment in an elderly diabetic patient with antisynthetase-associated interstitial lung disease"],"prefix":"10.2185","volume":"15","author":[{"given":"Kei","family":"Nagai","sequence":"first","affiliation":[{"name":"Kamisu Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Niisaka","sequence":"additional","affiliation":[{"name":"Kamisu Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Kamisu Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Sakata","sequence":"additional","affiliation":[{"name":"Kamisu Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Kamisu Saiseikai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"995","reference":[{"key":"1","unstructured":"1. Hochberg MC , Feldman D , Stevens MB , et al. Antibody to Jo-1 in polymyositis\/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984; 11: 663\u2013665."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Targoff IN , Trieu EP , Plotz PH , et al. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992; 35: 821\u2013830.","DOI":"10.1002\/art.1780350718"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hirakata M , Suwa A , Nagai S , et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999; 162: 2315\u20132320.","DOI":"10.4049\/jimmunol.162.4.2315"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wilkes MR , Sereika SM , Fertig N , et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52: 2439\u20132446.","DOI":"10.1002\/art.21240"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Takada K , Nagasaka K , Miyasaka N . Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38: 383\u2013392.","DOI":"10.1080\/08916930500124023"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Plotz PH , Dalakas M , Leff RL , et al. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med 1989; 111: 143\u2013157.","DOI":"10.7326\/0003-4819-111-2-143"},{"key":"7","unstructured":"7. Floersheim GL . Pharmacologic immunosuppressive agents. Transplant Proc 1980; 12: 315\u2013319."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamanishi Y , Maeda H , Konishi F , et al. Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. Scand J Rheumatol 1999; 28: 58\u201361.","DOI":"10.1080\/03009749950155805"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ito M , Kaise S , Suzuki S , et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 1999; 18: 462\u2013467.","DOI":"10.1007\/s100670050139"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yoshida S , Akizuki M , Mimori T , et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983; 26: 604\u2013611.","DOI":"10.1002\/art.1780260505"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bernstein RM , Morgan SH , Chapman J , et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984; 289: 151\u2013152.","DOI":"10.1136\/bmj.289.6438.151"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mimori T . Autoantibodies in connective tissue diseases: clinical significance and analysis of target autoantigens. Intern Med 1999; 38: 523\u2013532.","DOI":"10.2169\/internalmedicine.38.523"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Yoshifuji H , Fujii T , Kobayashi S , et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39: 233\u2013241.","DOI":"10.1080\/08916930600622884"},{"key":"14","unstructured":"14. Grau JM , Mir\u00f3 O , Pedrol E , et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996; 23: 1921\u20131926."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yoshida T , Koga H , Saitoh F , et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999; 38: 733\u2013738.","DOI":"10.2169\/internalmedicine.38.733"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Schnabel A , Reuter M , Gross WL . Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215\u20131220.","DOI":"10.1002\/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y"},{"key":"17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1378\/chest.103.1.69","volume":"103","year":"1993","unstructured":"17. Dayton CS , Schwartz DA , Helmers RA , et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 1993; 103: 69\u201373.","journal-title":"Chest","ISSN":"http:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Plosker GL , Foster RH . Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323\u2013389.","DOI":"10.2165\/00003495-200059020-00021"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Suwa A , Hirakata M , Kaneko Y , et al. Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report. Clin Rheumatol 2009; 28: 227\u2013229.","DOI":"10.1007\/s10067-008-1050-6"},{"key":"20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000194420","volume":"42","year":"1981","unstructured":"20. Costabel U , Matthys H . Different therapies and factors influencing response to therapy in idiopathic diffuse fibrosing alveolitis. Respiration 1981; 42: 141\u2013149.","journal-title":"Respiration","ISSN":"http:\/\/id.crossref.org\/issn\/0025-7931","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ishikawa H . Mizoribine and mycophenolate mofetil. Curr Med Chem 1999; 6: 575\u2013597.","DOI":"10.2174\/092986730607220401123549"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tsuchiya H , Tsuno H , Inoue M , et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 2014; 24: 694\u2013696.","DOI":"10.3109\/14397595.2013.874762"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Suda M , Kataoka Y , Tomishima Y , et al. Effectiveness of multi-target therapy in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with early-stage interstitial lung disease. Scand J Rheumatol 2017; 46: 505\u2013506.","DOI":"10.1080\/03009742.2017.1314004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Sauty A , Rochat T , Schoch OD , et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997; 10: 2907\u20132912.","DOI":"10.1183\/09031936.97.10122907"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Andersson H , Sem M , Lund MB , et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015; 54: 1420\u20131428.","DOI":"10.1093\/rheumatology\/kev004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Leclair V , Galindo-Feria AS , Dastmalchi M , et al. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology (Oxford) 2019; 58: 1214\u20131220.","DOI":"10.1093\/rheumatology\/key450"}],"container-title":["Journal of Rural Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jrm\/15\/4\/15_2020-018\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T19:40:19Z","timestamp":1696794019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jrm\/15\/4\/15_2020-018\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2185\/jrm.2020-018","relation":{},"ISSN":["1880-487X","1880-4888"],"issn-type":[{"value":"1880-487X","type":"print"},{"value":"1880-4888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}